Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

W J Sandborn; E V Loftus

doi:10.1136/gut.2003.020552

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

Gut. 2004 Jun;53(6):780-2. doi: 10.1136/gut.2003.020552.

Authors

W J Sandborn¹, E V Loftus

Affiliation

¹ Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. sandborn.william@mayo.edu

Abstract

Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / adverse effects*
Crohn Disease / drug therapy*
Gastrointestinal Agents / adverse effects*
Humans
Infliximab
Lymphoma, Non-Hodgkin / chemically induced
Opportunistic Infections / chemically induced
Risk Factors

Substances

Antibodies, Monoclonal
Gastrointestinal Agents
Infliximab